Dabur India - Q2FY21 Result - Angel Broking

Mr. Keshav Lahoti - Associate Equity Analyst, Angel Broking Ltd

"Dabur India Ltd reported a strong growth in its performance Q2FY21, backed by sustained efforts in driving demand for its Ayurvedic Healthcare, Hygiene and Nutrition products, coupled with strong innovation to meet the emerging consumer needs in the wake of the Covid pandemic. Dabur ended Q2FY21 with a 13.7% growth in consolidated revenue at Rs 2,516 crore, up from Rs. 2,212 crore a year earlier beating consensus estimate of Rs. 2320 crore. This is the highest revenue growth reported by the Company in the last couple of years. Dabur's FMCG business led the growth with a 19.8% surge, with an underlying FMCG volume growth of 16.8% during Q2FY21. Net profit rose by 20% to Rs. 483 crore was also above consensus estimate of Rs. 442 crore. Overall, numbers were above our expectation. We are bullish on Dabur India as it is beneficiary of Covid due to increased sales of immunity related products and increasing distribution reach of the Company."

Shares of DABUR INDIA LTD. was last trading in BSE at Rs.517.5 as compared to the previous close of Rs. 506.15. The total number of shares traded during the day was 318039 in over 6461 trades.

The stock hit an intraday high of Rs. 523.25 and intraday low of 509.75. The net turnover during the day was Rs. 164545220.

Source : Equity Bulls

Keywords